Regardless of whether they realize it, case managers have likely worked with patients who are living with Alzheimer’s disease or dementia. The diagnosis rate is relatively low. Even when a formal diagnosis is made, treatment is not necessarily offered — and for many patients, the diagnosis largely is overlooked.
Cholinesterase inhibitors are one of the few drug classes approved by the Food and Drug Administration for the treatment of patients with Alzheimer’s disease. This study shows a long-term benefit in slowing the decline of cognition, as measured by the Mini-Mental State Exam, but it is unclear if there is any benefit in quality of life.
Cadaveric pituitary-derived growth hormone that previously was known to transmit Creutzfeldt-Jakob disease (CJD) also contains ß-amyloid. Growth hormone vials from cases associated with amyloid plaques in CJD patients cause amyloid plaque formation and cerebral amyloid angiopathy when injected intracranially into mice.
In patients with clinically diagnosed dementia, the CSF biomarker profile of low CSF amyloid-ß1-42, high total tau, and high phosphorylated tau was seen in the majority of patients with clinically diagnosed Alzheimer’s disease. Substantial proportions of patients with non-Alzheimer’s dementia were also found to have the Alzheimer’s disease pathological profile. The value of CSF biomarker measurements in clinical practice is uncertain.